LEEDS, England, June 27, 2018 /PRNewswire/ --
4D pharma plc (AIM: DDDD), a
pharmaceutical company leading the development of live
biotherapeutics, today announced that the Company's Chief
Scientific Officer, Dr. Alex
Stevenson, has spoken at the International Human Microbiome
Consortium (IHMC) 2018 on the importance of function in the
development of live biotherapeutics.
"Ahead of World Microbiome Day, IHMC 2018 is an important event
which brings together thought leaders from across industry and
academia to discuss how we can translate microbiome science into
new therapies for patients," Dr. Alex
Stevenson commented.
He added, "It has become increasingly clear that understanding
bacterial function is of crucial importance in the development of
effective live biotherapeutics. This was one of the founding
principles of 4D pharma and we continue to lead the field,
leveraging this understanding to advance our candidates through the
clinic."
The presentation, entitled "Live Biotherapeutics - Form Follows
Function," highlights the historical development of other
therapeutic classes, how the active components of complex mixtures
have been isolated to create new types of drugs, and how we can
learn from this in the development of live biotherapeutics.
Please find a link to the presentation here:
https://www.4dpharmaplc.com/application/files/2715/3002/4005/4D_IHMC_2018.pdf
About 4D
Founded in February 2014, 4D is a
world leader in the development of live biotherapeutics, a novel
and emerging class of drugs, defined by the FDA as biological
products that contain a live organism, such as a bacteria, that is
applicable to the prevention, treatment or cure of a disease. 4D
has developed a proprietary platform that rationally identifies
novel bacteria that have a precise and evolved therapeutic effect.
All of 4D's live biotherapeutic products are orally delivered
single strains of bacteria that are naturally found in the healthy
human gut. 4D has completed a phase I study in Irritable Bowel
Syndrome and has recently completed dosing in a phase I study in
Paediatric Crohn's Disease. It currently has a pipeline of 13
pre-clinical programmes, covering disease areas such as cancer,
poorly controlled asthma, autoimmune and CNS disease, and plans to
commence four additional clinical studies in 2018.
For more information, please visit:
http://www.4dpharmaplc.com
About IHMC 2018
The 7th International Human Microbiome Consortium
meeting, which takes place 26th - 28th
June 2018 in Killarney, Ireland, is a world-renowned microbiome
conference featuring leading representatives from industry and
academia.
For more information, please visit:
http://apc.ucc.ie/ihmc-2018/
About World Microbiome Day
World Microbiome Day will showcase the vibrant and diverse world of
the microbiome and encourage dialogue on its critical importance to
human, animal and environmental health. World Microbiome Day has
been developed by APC Microbiome Ireland and will take place on
Wednesday June 27th 2018.
The day will be marked by events occurring throughout the world
including meetings at leading academic institutes and medical
centres across Europe, North and
South America, Asia and Australasia.
For more information, please visit:
http://worldmicrobiomeday.com/
For further details on APC Microbiome Ireland, please visit:
http://apc.ucc.ie/
For further information please contact:
4D
Duncan Peyton
Chief Executive Officer
+44(0)113-895-0130
Zeus Capital Limited - Nomad and Joint Broker
Dan Bate / Jordan Warburton
+44(0)161-831-1512
Bryan Garnier & Co. Limited -
Joint Broker
Dominic Wilson
Phil Walker
+44(0)20-7332-2500
SOURCE 4D Pharma PLC